Trial Profile

Phase 2, Double-Blind, Randomized, Placebo-Controlled Clinical Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Female Patients

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VYNT-0126 (Primary)
Indications Rett syndrome
Focus Adverse reactions; Proof of concept
Sponsors Vyant Bio

Most Recent Events

24 Nov 2022 Status changed from planning to not yet recruiting.
22 Aug 2022 According to a Vyant Bio media release, the company met with the Clinical Trial Committee of the International Rett Syndrome Foundation (IRSF) on July 19, 2022, to receive their feedback and guidance on this study. The company is on track to submit our clinical trial application to the Ethics Committee in Australia in the third quarter of 2022 for a trial to begin in early 2023.
03 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com